Antibodies for the treatment of synucleinopathy
First Claim
Patent Images
1. A monoclonal antibody which specifically binds to human alpha-synuclein and comprises:
- (a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO;
1;
(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO;
35;
(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO;
3;
(d) a Light Chain CDR1 comprising the amino acid sequence of SEQ ID NO;
4;
(e) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO;
5; and
(f) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO;
6.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson'"'"'s disease (including idiopathic and inherited forms of Parkinson'"'"'s disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer'"'"'s disease (LBV), Combined Alzheimer'"'"'s and Parkinson disease, pure autonomic failure and multiple system atrophy.
-
Citations
9 Claims
-
1. A monoclonal antibody which specifically binds to human alpha-synuclein and comprises:
-
(a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO;
1;(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO;
35;(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO;
3;(d) a Light Chain CDR1 comprising the amino acid sequence of SEQ ID NO;
4;(e) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO;
5; and(f) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO;
6. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
Specification